NRX Pharmaceuticals, Inc. current report, 24 May 2021

Full document

NRX Pharmaceuticals, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 24, 2021, details the completion of a business combination between Big Rock Partners Acquisition Corp. (BRPA) and NeuroRx, Inc. Following the merger, the combined entity operates as NRX Pharmaceuticals, Inc. (NRX), a holding company with equity interests in NeuroRx. The company ceased to be a shell company upon closing. Common stock and warrants began trading on the Nasdaq Global Market under the symbols "NRXP" and "NRXPW" on May 25, 2021.

Key Financial Metrics and Capital Structure

The filing does not provide specific revenue, profit, or cash flow figures for the combined entity within this document; such data is incorporated by reference from the Proxy Statement/Prospectus. However, the following capital structure and transaction metrics are disclosed:

  • PIPE Investment: The company consummated a Private Investment in Public Equity (PIPE) of $10,000,000, consisting of 1,000,000 shares of Common Stock at $10.00 per share.
  • Outstanding Shares: Following the transaction, there are 47,459,958 shares of Common Stock issued and outstanding.
  • Trust Account: Public shareholders had the right to redeem shares for a pro rata portion of the trust account, which held approximately $6.0 million (approximately $10.80 per share) as of April 23, 2021.
  • Consideration to NeuroRx: NeuroRx securityholders received 50,000,000 shares of Common Stock as closing consideration.
  • Contingent Consideration:
    • Earnout Shares: Up to 25,000,000 shares contingent on FDA Emergency Use Authorization (EUA) and New Drug Application (NDA) filing for the COVID-19 drug (ZYESAMI) by December 31, 2022.
    • Earnout Cash: Up to $100,000,000 in cash contingent on FDA approval and Orange Book listing for either the COVID-19 drug or the Antidepressant Drug Regimen (NRX-100/101) by December 31, 2022.

Material Changes and Corporate Actions

The primary material change is the transformation from a special purpose acquisition company (SPAC) to an operating biopharmaceutical holding company. Key changes include:

  • Management Changes: Jonathan C. Javitt was appointed CEO, Chairman, and Director. William Fricker was appointed CFO and Treasurer. Previous BRPA officers Richard Ackerman and Bennett Kim resigned.
  • Board Composition: The Board was reconstituted with six initial directors, later expanded to seven with the appointment of Lt. General H.R. McMaster. The company is classified as a "controlled company" due to the Javitt family's majority voting power.
  • Accountant Change: KPMG LLP was engaged as the independent registered public accounting firm, replacing Marcum LLP.
  • Lock-Up Agreements: Certain NeuroRx stockholders entered into lock-up agreements restricting share transfers for six months or until the stock price exceeds $12.00 per share for 20 trading days within a 30-day period.

Outlook, Risks, and Contingencies

Management's outlook is heavily dependent on regulatory milestones for its drug pipeline. The filing includes standard forward-looking statements regarding product development and commercialization.

  • Key Milestones: Future value is contingent on FDA actions regarding ZYESAMI (COVID-19) and NRX-100/101 (Antidepressant) by December 31, 2022.
  • Risk Factors: Significant risks include the company's limited operating history, dependence on regulatory approvals, competition, and the impact of the global COVID-19 pandemic. There are no guarantees that pipeline products will receive approval or be commercially successful.
  • Legal Proceedings: The company is subject to legal proceedings in the ordinary course of business but does not expect them to have a material adverse effect.
  • Dividends: The company has no current plans to pay cash dividends and intends to retain earnings for operations and expansion.

Investor Verification Checklist

  • Verify the specific terms and conditions of the Earnout Shares and Earnout Cash milestones in the Merger Agreement.
  • Review the "Selected Historical Consolidated Financial Information of NeuroRx" in the Proxy Statement/Prospectus for detailed revenue and cash burn data not present in this 8-K.
  • Confirm the status of the FDA Emergency Use Authorization (EUA) and New Drug Application (NDA) for ZYESAMI to assess the likelihood of the 25,000,000 share earnout.
  • Check the lock-up expiration dates for major shareholders, specifically the Javitt family and NeuroRx founders, to understand potential future selling pressure.
  • Review the "Risk Factors" section of the Proxy Statement for detailed disclosures on patent litigation and regulatory hurdles.